Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO Amit Kumar and Director Arnold Baskies continue to invest capital in Anixa.....
During his investor presentation, Dr. Kumar will discuss Anixa's portfolio of first-in-class oncology/immunology assets under development, with vaccines to prevent cancer and a CAR-T cell therapy to treat cancer. The Company's robust pipeline over the next 12 months includes three candidates based on two modalities, three indications, and two ongoing clinical trials.
https://ir.anixa.com/press-releases/detail/1037/anixa-biosciences-2024-annual-meeting-of-stockholders-to
cash$$$$-Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering, Haleon said. The value of the shares is roughly 2 billion pounds ($2.6 billion)
https://www.fiercepharma.com/pharma/pfizer-set-collect-26b-selloff-haleon-shares-reducing-stake-32-24#:~:text=Pfizer%20is%20set%20to%20reduce,billion)%2C%20according%20to%20Reuters.
$PFE - Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns. https://t.co/pKmu5AVN5e #trading #business #stocks
— Seeking Alpha (@SeekingAlpha) March 18, 2024
I actually see two_ danuglipron
https://www.pfizer.com/science/drug-product-pipeline
KEYTRUDA plus CRT is the first immunotherapy-based regimen to demonstrate a statistically significant improvement in OS in these patients
KEYNOTE-A18, also known as ENGOT-cx11/GOG-3047, is a randomized, double-blind Phase 3 trial
https://www.biospace.com/article/releases/merck-s-keytruda-pembrolizumab-plus-chemoradiotherapy-crt-significantly-improved-overall-survival-os-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/?keywords=pancreatic+cancer+phase+3
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Marke
https://finance.yahoo.com/news/pfizer-acquire-viking-therapeutics-eli-095000697.html
There's a big need for RSV vaccines. Even with two rivals already on the market, mRNA-1345 should be quite competitive, with its solid efficacy and prefilled syringe, which makes it easier for pharmacists and doctors.
Moderna also plans to file for FDA approval of its seasonal flu vaccine mRNA-1010 in 2024
Melanoma
Renal Cell Carcinoma
Carcinoma, Squamous Cell
Bladder Cancer
Non-small Cell Lung Cancer
https://clinicaltrials.gov/search?cond=mRNA-4157%20V940
write it in your brain----- $MRNA multibager$
all bullshit
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL)
https://www.biospace.com/article/releases/pfizer-announces-positive-overall-survival-in-phase-3-trial-of-adcetris-regimen-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-/?keywords=pancreatic+cancer+phase+3
CSCC is the second-most common form of skin cancer in the U.S.
Merck's immunotherapy Keytruda along with Moderna's MRNA-based vaccine are also being evaluated for the treatment of melanoma and non-small cell lung cancer
Analysts at Jefferies say this being the third late-stage study for the vaccine combination speaks to continued confidence in a broad program
Moderna Nears Its First Breakout In Over A Year After Launching Third Cancer Vaccine Test
The companies will test a combination of the cancer vaccine and Merck's blockbuster cancer drug, Keytruda, in patients with cutaneous squamous cell carcinoma
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024 "updates coming soon"
The RNA-catalyzed evolution of functional RNAs is thought to have been central to the early history of life on Earth and to the possibility of constructing RNA-based life in the laboratory
https://www.pnas.org/doi/10.1073/pnas.2321592121
https://gizmodo.com/rna-world-could-have-kickstarted-first-life-on-earth-1851310245
"Guinness World Records " Hypervaccinated’ man reportedly received 217 Covid jabs without side-effects
https://www.theguardian.com/society/2024/mar/06/hypervaccinated-man-217-covid-jabs-no-side-effects-germany
3 Reasons to Buy Moderna Stock
https://finance.yahoo.com/news/3-reasons-buy-moderna-stock-181000927.html
CDC panel mulls changes to RSV vaccine recommendation:
https://finance.yahoo.com/news/cdc-panel-mulls-changes-rsv-120000070.html
Moderna has submitted its vaccine for Food and Drug Administration approval, which is set to decide by mid-May. If approved, ACIP could recommend its use in June, Jefferies analyst Michael Yee wrote in a note to clients
Moderna spells out rare disease ambitions: 'We have a bunch of INDs planned'
https://endpts.com/moderna-spells-out-rare-disease-ambitions-we-have-a-bunch-of-inds-planned/
CDC Meeting on RSV Vaccines -this week
https://www.barrons.com/articles/gsk-moderna-stock-rsv-vaccines-26e5f86b
Seems to have all it takes......The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-LRTD as defined by two or more symptoms, and a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078) against RSV-LRTD defined by three or more symptoms.
only moderna...... the only pre-filled syringe product available at the time of launch.
"I read this" The PDUFA (Prescription Drug User Fee Act) action date for mRNA-1345 is May 12, 2024, by which time the Company expects the U.S. FDA's response to its Biologics License Application (BLA). If the outcome is positive, the Company anticipates that the U.S. CDC Advisory Committee on Immunization Practices (ACIP) will include mRNA-1345 on the agenda of its June 26-28 meeting. Assuming that corresponding marketing authorizations would be granted as expected, the Company also plans to launch its RSV vaccine in Australia and Germany in 2024 and other markets in 2025 due to regulatory and tender timing.
In the fall vaccination season, Moderna captured 48% of the COVID-19 retail market in the United States versus a 37% showing in 2022, closing the gap on Pfizer’s Comirnaty
Much of the call was focused on Moderna’s respiratory syncytial virus (RSV) vaccine, which is lined up for an FDA decision in May. The company appears poised to join a market competition with GSK’s Arexvy and Pfizer’s Abrysvo, which achieved 2023 sales of $1.5 billion and $890 million, respectively, in their first year on the market for people ages 60 and older.
The company sees the RSV market booming to $10 billion, with sales of between $6 billion to $8 billion in the older adult population.
https://www.fiercepharma.com/pharma/while-moderna-moving-covid-its-vaccine-gaining-share-pfizers-comirnaty
"it's written on the wall"The big news in Moderna's Q4 update was a surprise profit of $217 million, or $0.53 per share, based on generally accepted accounting principles (GAAP). The average analysts' estimate was for a Q4 loss of $0.90 per share.
Moderna also reported Q4 revenue of $2.8 billion, down from $5.1 billion in the prior-year period. However, this result was well above the consensus revenue estimate of $2.3 billion.
I don't think Moderna stock is a buy solely because of its Q4 results. My view is that risk-averse investors will be better off going with other stocks.
However, aggressive investors could find Moderna appealing right now. The company hopes to win U.S. regulatory approval for its respiratory syncytial virus (RSV) vaccine soon. It's also optimistic about filing for approval of seasonal flu vaccine mRNA-1010 this year. I predict Moderna's future will be brighter than its recent past.
https://www.fool.com/investing/2024/02/22/why-moderna-stock-is-jumping-today/
Moderna CEO: 2024 is year of growth, with 2023 transition in rearview
https://www.modernatx.com/en-US/media-center/all-media/blogs/recapping-q4-earnings-report-and-fiscal-year-2023
Moderna Expected to Beat Earnings Estimates
A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.
Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy
Who knows what does the future hold$$$$$$$
The new analysis included data from more than 36,000 participants, with median vaccine efficacy rates of 63.3% for RSV illnesses with two or more symptoms; 63% for three or more symptoms; and 53.9% against RSV-associated acute respiratory disease at an 8.6-month follow-up.
In the absence of head-to-head clinical trials, comparative conclusions regarding the safety and efficacy of mRNA-1345 relative to other RSV vaccines cannot be made. These trials differed in study populations, geographic locations, infection surveillance methods, and case definitions used for RSV.
Moderna is anticipating approvals of mRNA-1345 in the first half of 2024. The Company is encouraged by the strong competitive profile for its RSV vaccine, with robust efficacy data meeting all pre-specified statistical criteria, a well-established safety and tolerability profile, and as the only pre-filled syringe product available at the time of launch.
https://investors.modernatx.com/Statements--Perspectives/Statements--Perspectives-Details/2024/Statement-on-RSVVW-Abstract-on-mRNA-1345-2024-Rk2gVDGnqc/default.aspx
news imminent -$$$$$
On 13-16 February, 2024
https://resvinet.org/conferences/rsvvw24/
Statement on RSVVW Abstract on mRNA-1345
At an upcoming presentation at the RSVVW’24 conference, Moderna will share follow-up data from its ongoing ConquerRSV Phase 3 study of its investigational RSV vaccine candidate, mRNA-1345.
Moderna-backed Metagenomi cuts US IPO valuation target to $563 mln "speculation yesterday"
Moderna-backed Metagenomi:
Metagenomi Announces Pricing of Initial Public Offering
The shares are expected to begin trading on the Nasdaq Global Select Market on February 9, 2024 under the ticker symbol “MGX.” The offering is expected to close on February 13, 2024 subject to the satisfaction of customary closing conditions.
https://www.biospace.com/article/releases/metagenomi-announces-pricing-of-initial-public-offering/